Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line disease Exton, PA – March 19, 2026 — Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians
Saphnelo Surpasses Benlysta in CLE as Physicians Expand Use of Biologics Ahead of Key 2027 Catalysts
Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier in treatment. EXTON, PA — March 17, 2026 – As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted
New report using real-world data cites care hurdles, need for multiple meds In the U.S., having sickle cell disease (SCD) continues to place a heavy clinical burden on patients, who often require multiple medications, frequent blood transfusions, and the use of opioids to control pain. Most individuals with SCD report high barriers
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton, PA – March 10, 2026 – Spherix Global Insights today announced the release of its 2026 Patient Chart Dynamix™: Sickle Cell Disease (US) report, an in-depth analysis of 133 real-world patient charts collected from 86
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials. he FDA approveddeucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), the company announced March 7, 2026.¹ The decision makes deucravacitinib the first oral TYK2 inhibitor
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising off-label adoption of SGLT2 inhibitors. EXTON, PA — March 06, 2026 – New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and Roche’s PiaSky Exton, PA., March 5, 2026 — Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused on Market Access, expanding the company’s advisory capabilities to provide biopharma manufacturers and other stakeholders with comprehensive, data-driven insights across payer strategy, key account dynamics, organized customer engagement, and patient services
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. As the first med to selectively inhibit IL-17F as well as IL-17A, Bimzelx entered the crowded plaque psoriasis arena in 2023 before tacking on indications the
Findings show strong pre-launch awareness, safety-driven TYK2 differentiation from JAK inhibitors, and opportunity for Bristol Myers Squibb to strengthen rheumatology standing. EXTON, PA — February 27, 2026 — With the FDA’s March 6, 2026 PDUFA date approaching for Sotyktu (deucravacitinib) in psoriatic arthritis (PsA), new findings from RealTime Dynamix™: Psoriatic Arthritis Q1 (US), show that U.S. rheumatologists are actively monitoring the
Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for meaningful early momentum, according to the latest findings from Spherix Global Insights. Exton, PA., February 24, 2026 — Two months following the U.S. approval of Voyxact (sibeprenlimab) for IgA nephropathy (IgAN), new data from Spherix Global Insights
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Exton, PA, February 20, 2026 – The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA
Initial uptake reflects strong efficacy-driven positioning relative to established therapies, though familiarity gaps, payer controls, and measured promotional visibility shape the pace of adoption. EXTON, PA – February 17, 2026 – Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped
New Patient Voice Dynamix™ research highlights that even with patients’ high awareness of options and active engagement in their care, systemic barriers and personal limitations from ongoing severe pain keep many patients from experiencing optimal disease control. Exton, PA., February 5, 2026 — New research from Spherix Global Insights underscores
The FDA has rejected AstraZeneca’s subcutaneous version of lupus treatment Saphnelo, but the company is moving quickly to address the regulator’s concerns. (AstraZeneca) AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. The
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain hesitant on whether its efficacy outweighs the possible risks, according to survey data from Spherix Global Insights. “We are standing at the threshold of major change in rheumatology,” Sawyer May, insights director of rheumatology at Spherix Global Insights, told Healio. “The
